Edition:
India

Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

47.41USD
23 Aug 2016
Change (% chg)

$-0.08 (-0.17%)
Prev Close
$47.49
Open
$47.65
Day's High
$47.73
Day's Low
$47.32
Volume
312,247
Avg. Vol
312,454
52-wk High
$58.99
52-wk Low
$45.81

NVO.N

Chart for NVO.N

About

Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company's business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1),... (more)

Overall

Beta: 0.71
Market Cap(Mil.): $95,584.16
Shares Outstanding(Mil.): 2,012.56
Dividend: 0.45
Yield (%): 0.96

Financials

  NVO.N Industry Sector
P/E (TTM): 22.09 37.62 37.34
EPS (TTM): 2.15 -- --
ROI: 80.63 14.78 14.24
ROE: 88.29 15.65 15.22

BRIEF-Caverion delivers project for Novo Nordisk's new insulin production facility

* Caverion delivers a project for Novo Nordisk's new insulin production facility in Hillerød, Denmark

05 Aug 2016

NORDIC STOCKS - Factors to watch on Aug 5

The following stocks may be affected by newspaper reports and other factors on Friday:

05 Aug 2016

Novo Nordisk trims 2016 guidance, sees tough U.S. competition

COPENHAGEN, Aug 5 Denmark's Novo Nordisk narrowed its full-year profit growth guidance towards the lower end of a previously indicated target range, and said it sees intensified competition in the United States.

05 Aug 2016

NORDIC STOCKS - Factors to watch on Aug 5

The following stocks may be affected by newspaper reports and other factors on Friday:

05 Aug 2016

Lilly sales beat estimates, helped by newer drugs

Eli Lilly and Co on Tuesday reported better-than-expected quarterly sales, fueled by newer drugs, and predicted average annual revenue growth of at least 5 percent through the end of the decade due to its growing roster of medicines.

26 Jul 2016

UPDATE 3-Lilly sales beat estimates, helped by newer drugs

July 26 Eli Lilly and Co on Tuesday reported better-than-expected quarterly sales, fueled by newer drugs, and predicted average annual revenue growth of at least 5 percent through the end of the decade due to its growing roster of medicines.

26 Jul 2016

Novo Nordisk invests $60 mln to expand insulin plant in Kalundborg

* Danish pharmaceutical company Novo Nordisk is investing 400 million Danish crowns ($59.70 million) in a 500 square meter extension of the world's largest insulin production plant in Kalundborg, it said on Monday.

04 Jul 2016

Swiss stocks - Factors to watch on June 28

ZURICH, June 28 The Swiss blue-chip SMI was seen opening 1.1 percent higher at 7,676 points on Tuesday, according to premarket indications by bank Julius Baer .

28 Jun 2016

BRIEF-Ypsomed Holding collaborates with Novo Nordisk

* Collaborates with Novo Nordisk to provide new solutions in insulin pump therapy Source text: http://bit.ly/293IVRQ Further company coverage: (Gdynia Newsroom)

28 Jun 2016

BRIEF-Novo A/S, main owner of Novo Nordisk, appoints Kasim Kutay as new CEO

* Says appoints Kasim Kutay as new CEO from September 1, 2016

21 Jun 2016

Competitors

  Price Chg
Sanofi SA (SASY.PA) €69.29 +0.43
Eli Lilly and Co (LLY.N) $79.57 --

Earnings vs. Estimates